# V1 Empirics Check — openai/gpt-oss-120b (Variant A)

**Model:** openai/gpt-oss-120b
**Variant:** A
**Date:** 2026-03-24T16:15:29.875997

---

**1. Idea Fidelity**  
The paper follows the manifest closely. It uses the staggered adoption of permanent universal free‑meal mandates in eight states, exploits the CPS Food‑Security Supplement, and implements the triple‑difference (DDD) design that was outlined. The data construction (school‑age‑child indicator, treatment timing, pre‑treatment years) matches the original plan, and the authors even retain the “cohort” distinction that the manifest highlighted. One minor departure is the inclusion of the 2024‑effective states (New Mexico, Massachusetts) as “controls” even though the manifest listed them as a third cohort; this is acceptable because they are untreated during the sample period, but the paper should clarify that they are not used to estimate treatment effects. Overall, the paper does not miss any key element of the identification strategy, data source, or research question.

---

**2. Summary**  
The paper estimates the causal impact of state‑wide universal free school‑meal mandates on household food‑insecurity using a triple‑difference design that compares (i) treated vs. control states, (ii) households with vs. without school‑age children, and (iii) pre‑ vs. post‑mandate periods. Using 189 k household‑year observations from the CPS Food‑Security Supplement (2016‑2023), the authors find a precisely estimated null: universal meals do not appreciably change the share of food‑insecure households, even for low‑income or single‑parent families.

---

**3. Essential Points**  

1. **Validity of the Parallel‑Trends Assumption**  
   - The paper does not present any graphical or statistical tests of the key “parallel‑trends” assumption for the DDD. A visual of the food‑insecurity gap (school‑age vs. non‑school‑age) over the pre‑treatment years for treated and control states is essential. Without this, the credibility of the identification is uncertain, especially because 2021 is a pandemic year with universal waivers everywhere.  

2. **Treatment Timing and Post‑Period Specification**  
   - The “post” indicator is defined at the state level for each cohort, but the paper mixes 2022 (treated cohort 1) and 2023 (treated cohort 2) in a single specification. Because the post‑period length differs across cohorts (two versus one year), the DDD coefficient may be driven by cohort‑specific shocks. The authors should either (a) estimate cohort‑specific effects and then meta‑analyse them, or (b) use an event‑study framework that allows for varying leads/lags. The current “cohort 2” result (‑0.103, significant) looks like a spurious outlier and needs explanation.  

3. **Placebo and Falsification Tests**  
   - The only placebo presented uses households with children aged 0‑4. The coefficient is marginally significant and negative, which raises a flag: if the policy truly affects only school‑age children, the placebo should be indistinguishable from zero. The authors should add (i) a “no‑children” placebo (households with no children at all), (ii) a test that the DDD coefficient is unchanged when the treatment date is shifted one year earlier/later, and (iii) a test using outcomes that should not be affected (e.g., adult‑only health measures).  

*If these three concerns are not addressed, the paper should be rejected. If the authors can provide the additional evidence, the paper can proceed to revision.*

---

**4. Suggestions**  

1. **Parallel‑Trends Evidence**  
   - Plot the food‑insecurity gap (school‑age − non‑school‑age) for each state (or at least for treated vs. control averages) for 2016‑2021. Include confidence bands.  
   - Run event‑study regressions with leads and lags (e.g., three pre‑period leads, two post‑period lags) to formally test for pre‑trend differences. Report the coefficients and discuss any divergence.  

2. **Event‑Study / Cohort‑Specific Dynamics**  
   - Implement the Callaway‑Sant’Anna (2021) or Sun‑Abraham (2020) staggered‑DiD estimator to obtain cohort‑specific ATT estimates and to avoid the “negative weighting” problem of two‑way fixed effects with heterogeneous timing.  
   - Present an event‑study graph that shows the dynamic effect for each cohort separately. This will clarify whether the large negative coefficient for cohort 2 is a genuine effect or a mechanical artifact.  

3. **Refine the Placebo Strategy**  
   - Use households with *no* children as a stricter placebo; the coefficient should be exactly zero.  
   - Consider a falsification using a food‑security‑related outcome that should not react to school meals (e.g., adult‑only hunger‑related anxiety) if such a variable exists in the CPS.  
   - If the 0‑4‑year placebo remains marginally significant, discuss why spillovers (e.g., reduced household food‑budget pressure) might affect younger children, and adjust the interpretation accordingly.  

4. **Robust Standard Errors**  
   - With only six treated states, clustering at the state level can be unreliable. Complement the usual cluster‑robust SEs with wild‑cluster bootstrap or the Conley (1999) spatial HAC approach, and report the resulting confidence intervals.  

5. **Outcome Measurement Concerns**  
   - The CPS Food‑Security Supplement captures a 12‑month recall window, which may dilute short‑run effects of school meals. Discuss whether a “seasonal” sub‑sample (e.g., observations collected during the school year vs. summer) changes the result.  
   - If feasible, supplement the analysis with the USDA’s School‑Meal Participation data (e.g., state‑level NSLP participation rates) to show that the policy indeed raised participation among the newly‑eligible. This would strengthen the mechanism argument.  

6. **Heterogeneity Exploration**  
   - The income‑heterogeneity table shows a modestly positive (though insignificant) effect for households above 185 % FPL. Expand this analysis: plot the ATT across income deciles to see whether any narrow band experiences a measurable change.  
   - For single‑parent families, the estimate is noisy because of small cell size. Consider pooling across years or using a Bayesian hierarchical model to improve precision, or at least acknowledge the power limitation explicitly.  

7. **Policy Discussion**  
   - The discussion could be enriched by quantifying the “cost per percentage‑point reduction” that the null result implies. Even a null is informative for cost‑benefit analysis.  
   - Mention other channels (nutrition, attendance, academic achievement) that might justify universal meals despite the lack of food‑security impact, and suggest future work that could jointly estimate multiple outcomes.  

8. **Minor Presentation Issues**  
   - Table 1’s “Pre‑Treatment Summary Statistics” mixes weighted and unweighted numbers; clarify which weights are applied.  
   - In the regression tables, indicate the number of clusters used for the SEs.  
   - The notation D_s × K_i × P_{st} is a bit dense; a short footnote defining each term would aid readability.  
   - The bibliography includes a placeholder citation (“andreyeva2023universal”); replace it with the correct reference.  

9. **Replication Package**  
   - Provide a reproducible code repository with the exact API calls, data‑cleaning steps, and Stata/R/Python scripts used for the DiD estimations. This will allow reviewers and readers to verify that the treatment timing and household‑type definitions are implemented correctly.  

10. **Clarify the Role of the 2024 Cohort**  
    - Explain explicitly why New Mexico and Massachusetts are treated as controls rather than excluded, and verify that their inclusion does not bias the estimates (e.g., through anticipatory effects).  

---

**Overall Assessment**  
The paper tackles an important policy question with a promising natural‑experiment design and a high‑quality data source. The null finding is potentially policy‑relevant, but the credibility of the identification rests on demonstrating parallel trends, handling staggered adoption correctly, and presenting convincing falsification tests. Addressing the three essential points above (parallel‑trend verification, proper staggered‑DiD estimation, and robust placebos) will substantially strengthen the manuscript. With those revisions, the paper would make a solid contribution to the literature on universal versus means‑tested safety‑net programs.
